

S-Z DERMATOLOGY REFERRAL FORM

PATIENT INFORMATION				
Patient Name:		DOB:	Sex: <input type="checkbox"/> M <input type="checkbox"/> F <input type="checkbox"/> Other:	Weight: <input type="checkbox"/> lbs. <input type="checkbox"/> kg.
SSN:	Phone:	Allergies:		
Address:		City:	State:	Zip:
Emergency Contact:		Phone:	<input type="checkbox"/> Additional Information Attached	
PRESCRIBER INFORMATION				
Prescriber:		NPI:	DEA:	State Lic:
Supervising Physician:		Practice Name:		
Address:		City:	State:	Zip:
Phone:	Fax:	Key Office Contact:	Phone:	
DIAGNOSIS INFORMATION / MEDICAL ASSESSMENT				
Primary Diagnosis: <input type="checkbox"/> L28.1 Prurigo nodularis <input type="checkbox"/> L40.0 Psoriasis <input type="checkbox"/> L40.1; L40.2; L40.3, L40.4, L40.8, L40.54 Psoriatic arthritis <input type="checkbox"/> L40.59 <input type="checkbox"/> L50.1 Chronic Idiopathic Urticaria <input type="checkbox"/> L73.2 Hidradenitis Suppurativa <input type="checkbox"/> Other: _____				
Location: <input type="checkbox"/> Hands <input type="checkbox"/> Feet <input type="checkbox"/> Face <input type="checkbox"/> Scalp <input type="checkbox"/> Groin <input type="checkbox"/> Nails <input type="checkbox"/> Others: _____ Severity: <input type="checkbox"/> Mild (up to 3% BSA) <input type="checkbox"/> Moderate (3-10% BSA) <input type="checkbox"/> Severe (greater than 10% BSA), BSA _____ % If treated previously for this condition, please indicate which drugs have been tried and failed: _____ Date range of previous therapy: _____ Is patient currently on therapy? <input type="checkbox"/> Yes <input type="checkbox"/> No Type/ medication(s): _____ Will patient stop taking the above medication(s) before starting the new medication? <input type="checkbox"/> Yes <input type="checkbox"/> No, if yes, how long should patient wait before starting the new medication? _____ Has patient received a PPD (tuberculosis) Skin Test? <input type="checkbox"/> Yes <input type="checkbox"/> No Results: _____ Prior to initiating treatment and periodically during therapy, patient should be evaluated for active tuberculosis and tested for latent infection.				
PRESCRIPTION INFORMATION				
<input type="checkbox"/> STC Standard Protocol will include the following: (1) dispensing ordered med/dose, (2) diluent to mix and/or dilute dose, (3) flushes to flush line and anakit med (epinephrine 0.3 mg IM / 0.15 mg IM (for pediatric patients) and diphenhydramine 50 mg/mL) and (4) premeds to take 30 mins before orally (Apap 325 mg, may repeat x1, and diphenhydramine 25 mg, may repeat x1).				
Siliq ® <input type="checkbox"/> 210 mg/1.5 mL Prefilled Syringe (2 pack) <input type="checkbox"/> Starter Dose for Plaque Psoriasis: 210 mg SQ at weeks 0, 1 and 2, followed by maintenance dose <input type="checkbox"/> Maintenance Dose for Plaque Psoriasis: 210 mg SQ once every two weeks. (starting at week 2)		<input type="checkbox"/> Enroll in REMS Program QTY: <u>1 box (2 PFS)</u> Refills: <u>0</u> QTY: <u>1 box (2 PFS)</u> Refills: _____		
Simponi ® <input type="checkbox"/> Aria 50 mg/4 mL Patient weight (kg): _____ <input type="checkbox"/> Starter Dose: 2 mg/kg IV at weeks 0 and 4 <input type="checkbox"/> Maintenance Dose: 2 mg/kg IV every 8 weeks		<input type="checkbox"/> Enroll in SimponiOne® Program QTY: <u>1 month</u> Refills: <u>0</u> QTY: <u>QS for 8 weeks</u> Refills: _____		
Simponi ® <input type="checkbox"/> SmartJect 50 mg/0.5 mL <input type="checkbox"/> Prefilled Syringe 50 mg/0.5 mL *Pens will be dispensed if no preference is indicated <input type="checkbox"/> 50 mg SQ every month <input type="checkbox"/> Other: _____		QTY: <u>1 month</u> Refills: _____ QTY: _____ Refills: _____		
Skyrizi ® <input type="checkbox"/> Pen autoinjector 150mg/mL <input type="checkbox"/> Prefilled syringe 150mg/ml *Pens will be dispensed if no preference is indicated <input type="checkbox"/> Starter dose: 150 mg SQ at Week 0 and 4 <input type="checkbox"/> Maintenance Dose: 150 mg SQ every 12 Weeks		QTY: <u>1</u> Refills: <u>0</u> QTY: <u>1</u> Refills: _____		
Sotyku ® <input type="checkbox"/> 6mg po once daily		QTY: _____ Refills: _____		
Stelara ® <input type="checkbox"/> Prefilled Syringe <input type="checkbox"/> Vial <input type="checkbox"/> MD's Office Infusion <input type="checkbox"/> Home Infusion Supplies Required *Prefilled syringe will be dispensed if preference is not indicated <input type="checkbox"/> ≤ 100 kg Starter Dose: 45 mg SQ initially (week 0), then 45 mg SQ after 4 Weeks of initial dose (week 4) <input type="checkbox"/> ≤ 100 kg Maintenance Dose: 45 mg SQ every 12 Weeks <input type="checkbox"/> Other _____ <input type="checkbox"/> > 100 kg Starter Dose: 90 mg SQ initially (week 0), then 90 mg SQ after 4 Weeks of initial dose (week 4) <input type="checkbox"/> > 100 kg Maintenance Dose: 90 mg SQ every 12 Weeks <input type="checkbox"/> Other _____		<input type="checkbox"/> Enroll in Janssen CarePath Program QTY: <u>1 x 45mg</u> Refills: <u>1</u> QTY: <u>1 x 45mg</u> Refills: _____ QTY: <u>1 x 90mg</u> Refills: <u>1</u> QTY: <u>1 x 90mg</u> Refills: _____		
Taltz ® <input type="checkbox"/> Autoinjector 80 mg/mL <input type="checkbox"/> Prefilled Syringe 80 mg/mL *Pens will be dispensed if no preference is indicated <input type="checkbox"/> Starter Dose for Plaque Psoriasis: 160 mg (two 80 mg inj.) at Week 0, then 80 mg at Week 2,4,6,8,10,12 <input type="checkbox"/> Maintenance Dose for Plaque Psoriasis: 80 mg every 4 weeks <input type="checkbox"/> Starting Dose for Psoriatic Arthritis: 160 mg (two 80 mg inj.) at Week 0 <input type="checkbox"/> Maintenance Dose for Psoriatic Arthritis: 80 mg every 4 Weeks <input type="checkbox"/> Other _____		QTY: <u>8</u> Refills: <u>0</u> QTY: <u>1</u> Refills: _____ QTY: <u>2</u> Refills: <u>0</u> QTY: <u>1</u> Refills: _____ QTY: _____ Refills: _____		
Tremfya ® <input type="checkbox"/> Pen autoinjector 100 mg/mL <input type="checkbox"/> Prefilled syringe 100 mg/mL *Pen will be dispensed if no preference is indicated <input type="checkbox"/> Starter Dose: 100 mg SQ at Week 0, 4, and every 8 Weeks thereafter <input type="checkbox"/> Maintenance Dose: 100 mg SQ every 8 Weeks (starting at week 4)		QTY: <u>1</u> Refills: <u>0</u> QTY: <u>1</u> Refills: _____		
Xeljanz ® <input type="checkbox"/> 5mg tablet <input type="checkbox"/> 10mg tablet <input type="checkbox"/> 11mg ER tablet <input type="checkbox"/> 1 tablet po twice daily		QTY: <u>1 month</u> Refills: _____		
Xolair ® <input type="checkbox"/> Prefilled Syringe 150 mg <input type="checkbox"/> Vial 150 mg <input type="checkbox"/> 150mg SQ every 4 weeks <input type="checkbox"/> 300mg SQ every 4 weeks		QTY: <u>28 day supply</u> Refills: _____		

Prescriber's Signature: _____ DAW (Dispense as Written) **Date:** _____
 Prescriber certifies that this referral form contains an original signature and is signed by the treating prescriber. NO STAMPED SIGNATURES WILL BE ACCEPTED. Where required by law, send electronic prescription on official state prescription blank. Prescriber authorizes AcariaHealth to forward this prescription to another pharmacy, if needed.